Lab-grown insulin cells from human stem cells just reversed diabetes in mice, restoring normal blood sugar for months without drugs or gene editing.
Story Highlights
- Swedish researchers at Karolinska Institutet and KTH refined stem cell methods to produce pure, mature beta cells that sense and release insulin on demand.
- Transplanted into diabetic mice eyes, cells normalized blood sugar long-term, hinting at type 1 diabetes cures.
- Self-forming 3D clusters cut unwanted cells, boosting purity over 90% compared to older protocols.
- Patient-specific cells could slash immune rejection risks, paving way for human trials.
- Builds on decades of progress, from 2000 mouse injections to recent CRISPR fixes.
Breakthrough Stem Cell Protocol Emerges
Researchers at Karolinska Institutet and KTH Royal Institute of Technology in Sweden optimized differentiation of human pluripotent stem cells into insulin-producing beta cells. They adjusted culture conditions to let cells form three-dimensional clusters naturally. This step eliminated off-target cell types and enhanced glucose responsiveness. Published in Stem Cell Reports in 2026, the method yields uniform, mature cells ready for transplantation.
In lab tests, these beta cells secreted insulin precisely when glucose spiked. Transplanted into the anterior chamber of diabetic mice eyes, they gradually matured and regulated blood sugar for months. Mice regained normoglycemia without immunosuppression, a key hurdle cleared for type 1 diabetes treatments.
Key Researchers Drive Innovation
Per-Olof Berggren, professor at Karolinska’s Department of Molecular Medicine and Surgery, co-led the study. He emphasized patient-specific therapies to minimize rejection. Siqin Wu, now at Spiber Technologies AB, co-authored, bridging academia to biotech. Fredrik Lanner, professor of Clinical Science, highlighted how the method solves prior stem cell flaws, targeting clinical trials soon.
Teams chose the eye’s anterior chamber for transplants because it allows non-invasive monitoring via imaging. Cells integrated, functioned, and persisted, proving viability. This site avoids liver complications seen in traditional islet transplants.
Historical Precedents Fuel Momentum
Stem cell diabetes research traces to 2000, when University of Florida scientists injected progenitors to reverse murine diabetes. Progress surged with induced pluripotent stem cells in 2006 and scalable protocols post-2014. Recent advances include Washington University’s 2023 CRISPR edits for Wolfram syndrome mice and Utah’s 2020s glucagon antibody boosting insulin mass sevenfold.
Stanford’s 2024 hybrid immune systems enabled mismatched islet transplants without full suppression. China’s 2024 autologous stem cell transplant in a type 1 patient freed her from insulin needs. Karolinska’s work stands out for purity without editing or drugs.
Path to Human Cures Accelerates
Type 1 diabetes affects 8 million worldwide, costing billions yearly in the U.S. alone. This protocol supports scalable manufacturing for autologous cells, potentially ending lifelong immunosuppression and pumps. Short-term, it validates 3D clustering, speeding pipelines like Vertex’s implants. Long-term, it shifts from management to cures, promising equity if access expands.
Sources:
Scientists Create Improved Insulin Cells That Reverse Diabetes in Mice
These lab-grown insulin cells reverse diabetes in mice and clear a major hurdle for type 1 treatment
Diabetes reversed in mice with genetically edited patient-derived stem cells
Experimental treatment subdues Type 1 diabetes in laboratory mice
World’s first: stem cell therapy reverses diabetes – PMC – NIH
Scientists cured type 1 diabetes in mice by creating a blended immune system
